Results 81 to 90 of about 2,826,854 (328)

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection

Brazilian Journal of Veterinary Medicine, 2022
Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients ...
Carla Regina Gomes Rodrigues Santos, Isabela Torres Ferreira, Renata Beranger, Julia Possebon Santi, Mariana Palha de Brito Jardim, Heloisa Justen Moreira de Souza   +5 more
doaj   +1 more source

A bidirectional fluorescent two-hybrid system for monitoring protein–protein interactions

, 2014
Two-hybrid systems have been the cornerstone of research into protein–protein interactions, but these systems typically rely on life/death reporters that put additional selective pressure on the host organism, and potentially lead to false positives ...
Nordgren, Ida Karin, Tavassoli, Ali
core   +1 more source

Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. [PDF]

, 2017
Objective The contribution of hepatitis C virus (HCV) infection to the risk of heart failure in human immunodeficiency virus (HIV)-coinfected persons is unknown.
Ambale-Venkatesh, Bharath, Bluemke, David A, Butt, Adeel A, Chew, Kara W, Currier, Judith S, Horwich, Tamara B, Liao, Diana, Lima, João AC, Liu, Chia-Ying, Paul Finn, J   +9 more
core   +2 more sources

Integrase Strand Transfer Inhibitors in HIV Therapy [PDF]

Infectious Diseases and Therapy, 2013
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S.
Mark A. Wainberg, Mark A. Wainberg, Thibault Mesplède   +2 more
openaire   +2 more sources

Endogenously Triggered DNAzyme‐Based Nanostructures for Gene‐Combined Therapy

Advanced NanoBiomed Research, EarlyView.
DNAzymes show great promise for gene regulation and therapeutic use via controlled release triggered by endogenous factors. This review summarizes recent advances in designing and constructing nanoscale platforms enabling endogenously triggered release of DNAzyme.
Theoneste Muyizere, Julien Milon Essola, Eric Nyirimigabo, Janvier Mukiza, Jean Felix Mukerabigwi   +4 more
wiley   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

Engineered Hydrogels Revolutionize Locoregional Cancer Immunotherapy

Advanced NanoBiomed Research, EarlyView.
This review systematically summarizes the latest research progress on injectable hydrogels in cancer immunotherapy, highlighting their unique advantages in precise immune activation, local drug‐controlled release, and immune microenvironment remodeling. These features provide innovative solutions to overcome the bottlenecks of systemic side effects and
Jiyong Wei, Chunliu Huang, Zenghua Zhou, Yanni Lan   +3 more
wiley   +1 more source

Open-source genomic analysis of Shiga-toxin–producing E. coli O104:H4 [PDF]

, 2011
An outbreak caused by Shiga-toxin–producing Escherichia coli O104:H4 occurred in Germany in May and June of 2011, with more than 3000 persons infected. Here, we report a cluster of cases associated with a single family and describe an open-source genomic
Antoine Danchin, Cordesmeyer S, Dongfang Li, Fei Pu, Feng Xi, George F. Gao, Holger Rohde, Huanming Yang, Itoh Y, Jian Wang, Jianguo Xu, Jun Oh, Jun Wang, Junhua Li, Junjie Qin, Kuijper E, Liang Yang, Mark J. Pallen, Martin Aepfelbacher, Martin Christner, Meiru Zhao, Moritz Hentschke, Nicholas J. Loman, Peng Wang, Robin Kobbe, Ruifu Yang, Scheutz F, Sebastian Loos, Shenghui Li, Wentong Chen, Xiangna Zhao, Xianwei Yang, Yajun Song, Yangqing Peng, Yin Li, Yingrui Li, Yuanlin Guan, Yujun Cui, Zhaoxi Zhang, Zhong Cen   +39 more
core   +1 more source

Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting cabotegravir is approved for HIV treatment and prevention. To guide management of dosing deviations and interruptions, concentration‐time profiles for monthly and every 2 months regimens were simulated using a population pharmacokinetic (PPK) model.
Kelong Han, Ronald D. D'Amico, William R. Spreen, Susan L. Ford   +3 more
wiley   +1 more source

Resistance to novel drug classes [PDF]

, 2009
Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS: Integrase inhibitors and CCR5
Calvez, V., Ceccherini-Silberstein, F, Marcelin, AG, Perno, CF   +3 more
core   +1 more source